GlassScriptPhysician profile
Brett J Malbin
NPI 1902256787
$3,327.17
in general payments reported to CMS, 2019-2025
18 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $134 · 2021: $189 · 2022: $221 · 2023: $67.50 · 2024: $200 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $723.12 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $408.44 | 2019 | |
| Glaukos Corporation | $379.25 | 2019 | |
| Apellis Pharmaceuticals, INC. | $315.20 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $283.63 | 2023-2025 | Eylea Hd, Eylea |
| Mallinckrodt Enterprises LLC | $176.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $159.83 | 2019 | |
| Allergan, INC. | $158.03 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Genentech USA, INC. | $124.59 | 2023-2025 | Vabysmo, Susvimo |
| Shire North American Group INC | $114.85 | 2019 | |
| Astellas Pharma US INC | $70.59 | 2024-2025 | Izervay |
| Biotissue Holdings INC. | $66.30 | 2024-2025 | |
| Abbvie INC. | $22.97 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $22.74 | 2022 | |
| Biogen, INC. | $17.65 | 2022 | |
| Beaver-Visitec International, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Malbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.